| 1. |
- Engberg, Birgitta Anna, 1975-, et al.
(författare)
-
On the importance of fatigue for the rheological properties of wood
- 2009
-
Ingår i: Proceedings - 2009 International Mechanical Pulping Conference, IMPC 2009. ; , s. 239-244
-
Konferensbidrag (refereegranskat)abstract
- In this study the rheological properties of both native and fatigued wood was quantified under conditions relevant to mechanical pulping. This work was part of a Nordic cooperation project on "Basic phenomena in mechanical pulping. The new knowledge is intended to give us guidance on process development in mechanical pulping. The recent EES-concept [1] is assumed to offer low specific energy consumption mostly because of wood fatigue. A modulated loading device (MLD) developed at KCL was here used to fatigue wood samples. The samples were then evaluated by impulsive loading experiments carried out in an encapsulated Split-Hopkinson device (ESHD) developed at Mid Sweden University. Impulsive loadings, which extended to the non-elastic deformation region, were performed at four temperatures: 20, 65, 100 and 135°C. A higher testing temperature softened the wood samples to a high extent as could be expected. The results show that the reference samples (that was not subjected to fatigue treatment) had the highest stiffness in the investigation. The stress-strain curves of the fatigued samples were less steep, which indicate a softer more loosened material. It was evident that the fatigue treatment had loosened or weakened the wood material considerably and the differences were most pronounced at the two lowest testing temperatures.
|
|
| 2. |
|
|
| 3. |
- Jakobsen Falk, Ingrid, et al.
(författare)
-
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
- 2018
-
Ingår i: Cancer Chemotherapy and Pharmacology. - : SPRINGER. - 0344-5704 .- 1432-0843. ; 81:1, s. 183-193
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1 encodes the drug transporter P-glycoprotein, which confers resistance through drug extrusion across the cell membrane. Lenalidomide (Len) is excreted mainly via the kidneys, and, given the expression of P-gp in the renal tubuli, single-nucleotide polymorphisms (SNPs) in the ABCB1 gene may influence Len plasma concentrations and, subsequently, the outcome of treatment. We, therefore, investigated the influence of ABCB1 genetic variants on Len treatment outcomes and adverse events (AEs). Methods Ninety patients with relapsed or refractory MM, who received the second-line Len plus dexamethasone in the Rev II trial, were genotyped for the ABCB1 SNPs 1199G amp;gt; A (Ser400Asn, rs2229109), 1236C amp;gt; T (silent, rs1128503), 2677G amp;gt; T/A (Ala893Ser, rs2032582), and 3435C amp;gt; T (silent, rs1045642) using pyrosequencing, and correlations to response parameters, outcomes, and AEs were investigated. Results No significant associations were found between genotype and either best response rates or hematological AEs, and 1236C amp;gt; T, 2677G amp;gt; T or 3435C amp;gt; T genotypes had no impact on survival. There was a trend towards increased time to progression (TTP) in patients carrying the 1199A variant, and a significant difference in TTP between genotypes in patients with standard-risk cytogenetics. Conclusions Our findings show a limited influence of ABCB1 genotype on lenalidomide treatment efficacy and safety. The results suggest that 1199G amp;gt; A may be a marker of TTP following Len treatment in standard-risk patients; however, larger studies are needed to validate and clarify the relationship.
|
|
| 4. |
- Liwing, Johan, et al.
(författare)
-
Improved survival in myeloma patients : starting to close in on the gap between elderly patients and a matched normal population
- 2014
-
Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 164:5, s. 684-693
-
Tidskriftsartikel (refereegranskat)abstract
- The outcome for multiple myeloma patients has improved since the introduction of bortezomib, thalidomide and lenalidomide. However, studies comparing new and conventional treatment include selected patient groups. We investigated consecutive patients (n = 1638) diagnosed in a defined period and compared survival with a gender- and age-matched cohort Swedish population (n = 9 340 682). Median overall survival for non-high-dose treated patients was 2.8 years. The use of bortezomib, thalidomide or lenalidomide in first line therapy predicted a significantly longer overall survival (median 4.9 years) compared to conventional treatment (2.3 years). Among non-high-dose treated patients receiving at least 2 lines with bortezomib, thalidomide or lenalidomide, 69% and 63% have survived at 3 and 5 years as compared to 48% and 22% with conventional drugs and 88% and 79% in the matched cohort populations, respectively. The median overall survival in high-dose treated patients was 6.9 years. Of these patients, 84% survived at 3 years and 70% at 5 years as compared to 98% and 95% in the matched cohort population. Overall survival in the best non-high-dose treated outcome group is closing the gap with the matched cohort. Upfront use of new drugs is clearly better than waiting until later lines of treatment.
|
|
| 5. |
- Lund, Johan, et al.
(författare)
-
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
- 2018
-
Ingår i: Cancer Medicine. - : WILEY. - 2045-7634. ; 7:6, s. 2256-2268
-
Tidskriftsartikel (refereegranskat)abstract
- Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25mg/day) or Len+Dex (25mg/day and 40mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9months (95% confidence interval 12.5-not calculable, P amp;lt; 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile.
|
|
| 6. |
- Mattsson, Agnes, et al.
(författare)
-
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia : A Swedish nation-wide real-world report on consecutively identified patients
- 2023
-
Ingår i: European Journal of Haematology. - : John Wiley & Sons. - 0902-4441 .- 1600-0609. ; 111:5, s. 715-721
-
Tidskriftsartikel (refereegranskat)abstract
- ObjectivesWe examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL).Methods and ResultsThirty-seven patients with relapsed/refractory disease were included. The median number of prior lines of therapy was 3 (range 1–11); the median age was 69 years (range 50–89); 22% had Cumulative Illness Rating Scale (CIRS) >6 and 51% had del(17p)/TP53 mutation. The overall response rate was 65% (all but one was partial response [PR]). The median duration of therapy was 9.8 months (range 0.9–44.8). The median progression-free survival was 16.4 months (95% CI: 10.4–26.3) and median overall survival had not been reached (75% remained alive at 24 months of follow-up). The most common reason for cessation of therapy was colitis (n = 8, of which seven patients experienced grade ≥3 colitis). The most common serious adverse event was grade ≥3 infection, which occurred in 24 patients (65%).ConclusionsOur real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2.
|
|
| 7. |
- Moilanen, Carolina, et al.
(författare)
-
Influence of strain rate, temperature and fatigue on the radial compression behaviour of Norway spruce
- 2017
-
Ingår i: Holzforschung. - : Walter de Gruyter GmbH. - 0018-3830 .- 1437-434X. ; 71:6, s. 505-514
-
Tidskriftsartikel (refereegranskat)abstract
- A dynamic elastoplastic compression model of Norway spruce for virtual computer optimization of mechanical pulping processes was developed. The empirical wood behaviour was fitted to a Voigt-Kelvin material model, which is based on quasi static compression and high strain rate compression tests (QSCT and HSRT, respectively) of wood at room temperature and at high temperature (80-100 degrees C). The effect of wood fatigue was also included in the model. Wood compression stress-strain curves have an initial linear elastic region, a plateau region and a densification region. The latter was not reached in the HSRT. Earlywood (EW) and latewood (LW) contributions were considered separately. In the radial direction, the wood structure is layered and can well be modelled by serially loaded layers. The EW model was a two part linear model and the LW was modelled by a linear model, both with a strain rate dependent term. The model corresponds well to the measured values and this is the first compression model for EW and LW that is based on experiments under conditions close to those used in mechanical pulping.
|
|
| 8. |
- Moilanen, Carolina S., et al.
(författare)
-
High strain rate radial compression of Norway spruce earlywood and latewood
- 2016
-
Ingår i: Cellulose. - : Springer Science and Business Media LLC. - 0969-0239 .- 1572-882X. ; 23:1, s. 873-889
-
Tidskriftsartikel (refereegranskat)abstract
- The mechanical properties of Norway spruce were studied and a compression model for mechanical pulping was developed. The split-Hopkinson pressure bar technique was combined with high-speed photography to analyse local radial compression. Data analysis focussed on the differences between mechanical properties of earlywood and latewood. Measurements were conducted at both room temperature and 135 C. The effect of prefatigue treatment was also studied. A simple material model was defined linearly in parts and fitted to the measurement data to quantify the differences. New results were found on the differences in inelastic behaviour of earlywood and latewood at large deformations. In addition, other results were in line with previously published results.
|
|
| 9. |
|
|
| 10. |
- Nevonen, Lauri, et al.
(författare)
-
Evaluation of a new Internet-based self-help guide for patients with bulimic symptoms in Sweden.
- 2006
-
Ingår i: Nordic journal of psychiatry. - : Informa UK Limited. - 0803-9488 .- 1502-4725. ; 60:6, s. 463-8
-
Tidskriftsartikel (refereegranskat)abstract
- The current study evaluated a new Internet-based self-help guide based on cognitive-behavioural therapy for patients with bulimic symptoms. Thirty-eight participants from a waiting list at an eating-disorder outpatient unit were assessed pre-treatment, post-treatment and at a 2-month follow-up using the Rating of Anorexia and Bulimia interview-revised version, an anamnesis questionnaire, the Eating Disorder Inventory-2 (EDI-2) and Symptom Check List-90-Revised (SCL-90R). The SCL-90R Global Severity Index and most EDI-2 subscales showed significant differences from pre-to post-treatment and the 2-month follow-up, apart from ineffectiveness, impulse regulation and social insecurity. Expert ratings revealed a significant reduction in vomiting, dietary restraints and weight phobia, with the exception of binge eating from pre-treatment to the 2-month follow-up. Exercise increased significantly, indicating that participants changed their method of compensation. An Internet-based self-help guide for bulimic symptoms is a promising new tool and can be used effectively as the first step in a stepped-care model. Further evaluations with randomized controlled trials are necessary.
|
|
